Buscar
Compugen Ltd
CGENAñadir a la lista de seguimiento
2.822USD
-0.208-6.87%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
263.94MCap. mercado
7.46P/E TTM
Más Datos de Compugen Ltd Compañía
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Información de Compugen Ltd
Símbolo de cotizaciónCGEN
Nombre de la empresaCompugen Ltd
Fecha de salida a bolsaAug 01, 2000
Director ejecutivoOphir (Eran)
Número de empleados74
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 01
DirecciónAzrieli Center
CiudadHOLON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIsrael
Código postal5885849
Teléfono97237658585
Sitio Webhttps://cgen.com/
Símbolo de cotizaciónCGEN
Fecha de salida a bolsaAug 01, 2000
Director ejecutivoOphir (Eran)
Ejecutivos de Compugen Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Anat Cohen-Dayag, Ph.D.
Dr. Anat Cohen-Dayag, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
75.81K
+25.97%
Dr. Zurit Levine, Ph.D.
Dr. Zurit Levine, Ph.D.
Senior Vice President, Technology Innovation
Senior Vice President, Technology Innovation
29.38K
--
Mr. Gilead Halevy
Mr. Gilead Halevy
Independent Director
Independent Director
11.41K
--
Mr. Eran Ophir
Mr. Eran Ophir
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.38K
--
Dr. Kinneret Livnat Savitsky, Ph.D.
Dr. Kinneret Livnat Savitsky, Ph.D.
Independent Director
Independent Director
--
--
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Sanford (Sandy) Zweifach, CPA
Mr. Sanford (Sandy) Zweifach, CPA
Independent Director
Independent Director
--
--
Mr. Eran Perry
Mr. Eran Perry
Independent Director
Independent Director
--
--
Dr. Oliver Froescheis, Ph.D.
Dr. Oliver Froescheis, Ph.D.
Senior Vice President, Corporate and Business Development
Senior Vice President, Corporate and Business Development
--
--
Dr. Yaron Turpaz, Ph.D.
Dr. Yaron Turpaz, Ph.D.
Senior Vice President, Senior Advisor, Computational Discovery
Senior Vice President, Senior Advisor, Computational Discovery
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Anat Cohen-Dayag, Ph.D.
Dr. Anat Cohen-Dayag, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
75.81K
+25.97%
Dr. Zurit Levine, Ph.D.
Dr. Zurit Levine, Ph.D.
Senior Vice President, Technology Innovation
Senior Vice President, Technology Innovation
29.38K
--
Mr. Gilead Halevy
Mr. Gilead Halevy
Independent Director
Independent Director
11.41K
--
Mr. Eran Ophir
Mr. Eran Ophir
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.38K
--
Dr. Kinneret Livnat Savitsky, Ph.D.
Dr. Kinneret Livnat Savitsky, Ph.D.
Independent Director
Independent Director
--
--
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de abr
Divisa: USDActualizado: lun., 6 de abr
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United Kingdom
65.00M
89.33%
United States
7.76M
10.67%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: jue., 14 de may
Actualizado: jue., 14 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
SilverArc Capital Management, LLC
3.68%
Bristol Myers Squibb
1.95%
Renaissance Technologies LLC
1.54%
ARK Investment Management LLC
1.11%
Nomura Investment Management Business Trust
1.08%
Otro
90.64%
Accionistas
Accionistas
Proporción
SilverArc Capital Management, LLC
3.68%
Bristol Myers Squibb
1.95%
Renaissance Technologies LLC
1.54%
ARK Investment Management LLC
1.11%
Nomura Investment Management Business Trust
1.08%
Otro
90.64%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
6.27%
Investment Advisor
6.17%
Corporation
1.95%
Investment Advisor/Hedge Fund
1.49%
Research Firm
0.48%
Individual Investor
0.14%
Venture Capital
0.07%
Bank and Trust
0.07%
Family Office
0.04%
Otro
83.33%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
124
13.75M
14.54%
+445.22K
2025Q4
119
12.73M
17.35%
--
2025Q3
125
12.73M
18.34%
-2.70M
2025Q2
126
16.23M
19.87%
+39.65K
2025Q1
133
16.24M
16.64%
+1.34M
2024Q4
138
13.37M
17.09%
+210.15K
2024Q3
152
13.17M
21.08%
-305.68K
2024Q2
162
13.42M
29.55%
-531.69K
2024Q1
196
13.93M
29.95%
-12.89M
2023Q4
205
11.91M
32.36%
-1.05M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
SilverArc Capital Management, LLC
3.48M
3.68%
+168.64K
+5.09%
Dec 31, 2025
Bristol Myers Squibb
1.84M
1.95%
-2.92M
-61.32%
Dec 31, 2024
Renaissance Technologies LLC
1.46M
1.54%
+51.56K
+3.67%
Dec 31, 2025
Nomura Investment Management Business Trust
1.02M
1.08%
--
--
Dec 31, 2025
Taylor Frigon Capital Management LLC
869.23K
0.92%
-95.48K
-9.90%
Dec 31, 2025
Morgan Stanley Smith Barney LLC
840.06K
0.89%
-30.75K
-3.53%
Dec 31, 2025
Northern Trust Global Investments Limited
658.91K
0.7%
--
--
Dec 31, 2025
Two Sigma Investments, LP
552.83K
0.58%
+97.17K
+21.32%
Dec 31, 2025
State Street Investment Management (US)
393.80K
0.42%
+14.70K
+3.88%
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
SPDR S&P International Small Cap ETF
0.01%
Invesco NASDAQ Future Gen 200 ETF
0%
ARK Israel Innovative Technology ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
SPDR S&P International Small Cap ETF
Proporción0.01%
Invesco NASDAQ Future Gen 200 ETF
Proporción0%
ARK Israel Innovative Technology ETF
Proporción0%
SPDR Portfolio Developed World ex-US ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
